Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Controlled, Observer-blinded Phase III Clinical Trial to Compare the Effect of Intravenous Ferric Carboxymaltose to Placebo on Exercise Capacity and Cardiac Function in Patients With Chronic Heart Failure and Iron Deficiency

NCT00821717 is registered in ClinicalTrials.gov with Vifor Pharma as lead sponsor.

NCT NCT00821717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00821717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Controlled, Observer-blinded Phase III Clinical Trial to Compare the Effect of Intravenous Ferric Carboxymaltose to Placebo on Exercise Capacity and Cardiac Function in Patients With Chronic Heart Failure and Iron Deficiency
Lead sponsor
Vifor Pharma
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2008
Completion date
January 31, 2011
Enrollment
35 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

anaemia, chronic heart failure, iron deficiency, iron deficiency anemia